Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manufacture TfR1 CapX, a Next-Generation Capsid for Gene Therapies Designed to Treat Central Nervous System Diseases

Viralgen New York Spain California

and follow us on LinkedIn.

About Apertura Gene Therapy

Apertura Gene Therapy develops genetic medicines and next-generation AAV capsids that engage human-relevant receptors, aiming to enable more effective and selective gene delivery. The company's lead capsid, TfR1 CapX, leverages human transferrin receptor 1 to enable intravenous delivery to the brain and spinal cord. This established transport mechanism has a strong clinical track record in pediatric and geriatric populations, expanding its potential to treat serious neurological and genetic diseases. Apertura has licensed its next-generation capsids to multiple partners, with programs expected to enter clinical trials this year and next year. Founded in 2021 on technology from the Broad Institute and supported by Deerfield Management Company, Apertura Gene Therapy is headquartered in New York City. Learn more at aperturagtx.com and follow us on LinkedIn.

Photo - https://mma.prnewswire.com/media/2933520/Viralgen__Viralgen_laboratory.jpg
Logo - https://mma.prnewswire.com/media/2592385/Viralgen__logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/apertura-gene-therapy-and-viralgen-announce-strategic-collaboration-to-manufacture-tfr1-capx-a-next-generation-capsid-for-gene-therapies-designed-to-treat-central-nervous-system-diseases-302714462.html